Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months - not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Huang Yuguang on the use of ERAS and TIVA in China

There is no excerpt because this is a protected post.

Aspen CSA2017 the status of ERAS in China CSA2017 on the use of ERAS and TIVA in China

CSA2017: Prof Xiong Lize on the status of ERAS in China

There is no excerpt because this is a protected post.

25th Annual Meeting of the Chinese Society of Anaesthesiology

Almost 10,000 doctors from China joining together to learn about the latest developments in anaesthesiology. Impressions of the 25th Annual Meeting of the Chinese Society of Anaesthesiology - CSA2017 - 中华医学会第25 次全国麻醉学术年会